Importantly, patients with MDS and AML who failed to respond to AZA exhibited increased pre-treatment levels of the CD8+CD57+CXCR3+ subset compared to responders, who instead displayed a higher baseline abundance of Tn cells [163]. The gene discussed is CD8A; the disease is acute myeloid leukemia.